Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2016-08-31
2018-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy
NCT02397603
Para-vertebral Dexmedetomidine and the Incidence of Postoperative Chronic Pain
NCT03632161
Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks
NCT02619513
Dexmedetomidine Versus Dexamethasone as Adjuvants to Bupivacaine for Intermediate Cervical Plexus Block
NCT05793060
Dexmedetomidine and Fentanyl as Adjuvants to Thoracic Epidural
NCT06489574
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients will be allocated randomly into two equal groups by computer programs and will be contained in sealed opaque envelopes.
Patients will be premedicated with midazolam (0.1mg/kg), 30 min before the operation. Patients will be monitored with ECG, non-invasive blood pressure, heart rate, temperature, oxygen saturation, exhaled CO2 (end tidal capnography), and train of four. In both groups, general anesthesia will be induced with propofol (2mg/kg) and fentanyl (1 mcg/kg). Tracheal intubation will be facilitated with cisatracurium 0.1 mg/kg. Anesthesia will be maintained with isoflurane (1-2 %) and cisatracurium (0.05 mg/kg per dose). Fentanyl (0.5mcg/kg) will be repeated if heart rate (HR) and/or mean arterial pressure (MAP) rise 20 % above baseline values. After the end of anesthesia induction and before surgical procedure Technique of ultrasound guided paravertebral block will be done in both groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A
Ultrasound guided paravertebral block with bupivacaine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) via paravertebral route.
Bupivacaine
Ultrasound guided paravertebral block with bupivacaine
Group B
Ultrasound guided paravertebral block with bupivacaine and dexmedetomidine group Thirty patients will be given isobaric bupivacaine 0.5% (0.3ml/kg) and dexmedetomidine (1 mcg/kg) via paravertebral route (Bupivacaine plus Dexmedetomidine)
Bupivacaine
Ultrasound guided paravertebral block with bupivacaine
Dexmedetomidine
Ultrasound guided paravertebral block with dexmedetomidine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupivacaine
Ultrasound guided paravertebral block with bupivacaine
Dexmedetomidine
Ultrasound guided paravertebral block with dexmedetomidine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. In the age ranged between 18 up to 60 years.
3. Elective video-assisted thoracoscopy
Exclusion Criteria
2. Liver impairment
3. Renal impairment
4. allergy to the drugs used
5. Known contraindication for regional techniques such as:
* Infection near the site of the needle insertion
* Coagulopathy
* Anti-coagulation therapy,
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sayed Kaoud Abd-Elshafy
Associate profossor of anesthesia
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sayed K Abd-Elshafy, MD
Role: PRINCIPAL_INVESTIGATOR
Associate professor of anesthesia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIRB0000871250
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.